Emeryville Cancer Drug Developer Eureka Therapeutics Lands $21 Million From Chinese, Other Investors

Cancer therapy developer Eureka Therapeutics Inc. snagged $21 million in a Series C round led by Chinese private equity firm Yuan Capital.

The funding round, which included previous investors Acorn Campus Ventures, Suma Venture and Harbinger Venture Capital, will be used to expand the Emeryville company's cancer immunotherapy portfolio and take its lead programs into human clinical trials.

Help employers find you! Check out all the jobs and post your resume.